Axsome Therapeutics AXSM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$64.54M-8.6% | -$28.56M+61.9% | -$47.23M+26.9% | -$47.97M+39.5% | -$59.41M+13.1% | ||
| $116K-22.1% | $114K-11.6% | $120K-8.4% | $120K-14.3% | $149K+12.9% | ||
| $23.44M+0.6% | $22.73M+3.4% | $23.1M+6.7% | $24.61M+15.1% | $23.31M+15.4% | ||
| $26.6M+37.1% | $27.96M+56.1% | $0-100% | $37.43M+98.0% | $19.4M+193% | ||
| $3.11M+1,149% | $3.64M— | $4.99M+488% | $1.78M+358% | $249K+137% | ||
| $41.17M+201% | —— | -$37.4M-1,384% | $5.97M-20.9% | $13.66M+4.2% | ||
| $17.23M+2,006% | $7.17M-72.1% | $54.25M+919% | $21.5M-35.8% | $818K+110% | ||
| $1.57M0.0% | $1.61M0.0% | $1.61M+0.1% | $1.59M-0.1% | $1.57M-1.1% | ||
| -$608K-392% | —— | —— | —— | $208K+297% | ||
| $159K-76.2% | $161K-77.3% | $158K-76.5% | $317K-50.5% | $667K+7.8% | ||
| -$20.7M+52.3% | -$18.65M+28.8% | $0+100% | -$32.42M-7.7% | -$43.38M+18.9% | ||
| $121K-64.2% | $71K+137% | $58K-35.6% | $13K-75.0% | $338K+245% | ||
| -$121K+64.2% | -$71K-137% | -$58K+35.6% | -$13K+75.0% | -$338K-245% | ||
| $70M— | $70M— | $70M— | —— | —— | ||
| $6.34M-67.7% | $5.68M-65.4% | $9.95M-24.1% | $32.63M+272% | $19.65M+686% | ||
| $672K+67.6% | $541K+63.9% | $664K+114% | $518K+178% | $401K+146% | ||
| $9.3M+115% | $1.04M+95.9% | $842K+78.0% | $888K-33.1% | $4.34M+168% | ||
| $2.99M-89.8% | $16.39M+15.0% | $21.27M-30.1% | $34.54M+140% | $29.27M+2,566% | ||
| -$17.83M-23.4% | —— | $22.26M— | —— | -$14.44M+73.6% | ||
| $2.93M-36.1% | $3.05M-35.9% | $3.22M-36.0% | $3.77M-24.7% | $4.59M-6.4% | ||
| $159K-76.2% | $161K-77.3% | $158K-76.5% | $317K-50.5% | $667K+7.8% | ||
| $1.57M0.0% | $1.61M0.0% | $1.61M+0.1% | $1.59M-0.1% | $1.57M-1.1% | ||
| $590K-61.0% | -$9.07M-183% | $13.19M-19.6% | -$8.1M-475% | $1.51M+207% | ||
| $116K-22.1% | $114K-11.6% | $120K-8.4% | $120K-14.3% | $149K+12.9% | ||
| —— | —— | —— | —— | $2.25M— | ||
| -$608K-392% | —— | —— | —— | $208K+297% | ||
| $17.23M+2,006% | $7.17M-72.1% | $54.25M+919% | $21.5M-35.8% | $818K+110% | ||
| $9.87M+145% | —— | $3.45M+115% | $331K— | $4.03M+2.9% | ||
| $844K+38.6% | $797K+130% | $817K+140% | $823K+141% | $609K+69.2% | ||
| $1.76M+84.5% | $0-100% | $1.94M— | $2.27M+1,300% | $955K+10.1% | ||
| $672K+67.6% | $541K+63.9% | $664K+114% | $518K+178% | $401K+146% | ||
| -$3.26M-42.8% | -$2.95M-38.2% | -$2.51M-29.2% | -$2.2M-16.7% | -$2.29M-19.8% | ||
| $95K-75.8% | $98K-70.2% | $189K-27.9% | $517K+130% | $393K— | ||
| $9.98M-41.4% | $15.34M+1,236% | $15.52M-23.5% | $11.66M— | $17.04M— | ||
| $679K+64.8% | $553K+64.1% | $684K+111% | $537K+104% | $412K+275% | ||
| $70M— | $70M— | $70M— | —— | —— | ||
| $3.43M+124% | $115K-75.3% | $2.04M+540% | $828K-60.2% | $1.53M-38.5% | ||
| —— | —— | —— | —— | $23.87M— | ||
| —— | —— | —— | —— | $7.6M— | ||
| -$20.82M+52.4% | -$18.72M+28.6% | $0+100% | -$32.44M-7.5% | -$43.71M+18.4% | ||
| -$20.82M+52.4% | -$18.72M+28.6% | $0+100% | -$32.44M-7.5% | -$43.71M+18.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Axsome Therapeutics generate?
- Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
- What is Axsome Therapeutics's free cash flow?
- After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
- Where does Axsome Therapeutics's cash flow data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
